Krka monitors situation in Ukraine closely, expects no long-term effects

Novo Mesto – Drug company Krka, which has significant exposure to the Russian and Ukrainian markets, said on Thursday it could not yet assess the impact of the current situation in these two countries on its operations in 2022. But it stressed it had a strong capital structure, robust money flow and no financial debt, so long-term operations were not at risk. According to unaudited consolidated business results, Krka generated EUR 1.57 billion in revenue in 2021, up 2% from 2020. Net profit was up 7% to EUR 308.2 million,…

For FREE further reading please JUST enter your email address

I allow to collect my email data for analytics and email campaign